Exscientia plc Logo

Exscientia plc

EXAI

(1.0)
Stock Price

5,20 USD

-29.54% ROA

-33.09% ROE

-4.4x PER

Market Cap.

593.440.023,68 USD

4.66% DER

0% Yield

-587.75% NPM

Exscientia plc Stock Analysis

Exscientia plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Exscientia plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (4%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.45x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

Negative ROE (-31.84%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-30.41%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-455), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Exscientia plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Exscientia plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Exscientia plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Exscientia plc Revenue
Year Revenue Growth
2019 11.940.788
2020 13.181.242 9.41%
2021 27.414.780 51.92%
2022 32.900.000 16.67%
2023 35.528.000 7.4%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Exscientia plc Research and Development Expenses
Year Research and Development Expenses Growth
2019 8.746.788
2020 14.877.959 41.21%
2021 44.085.930 66.25%
2022 155.600.000 71.67%
2023 126.840.000 -22.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Exscientia plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 6.212.304
2020 12.160.486 48.91%
2021 25.784.712 52.84%
2022 46.400.000 44.43%
2023 44.564.000 -4.12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Exscientia plc EBITDA
Year EBITDA Growth
2019 -8.714.008
2020 -31.651.607 72.47%
2021 -56.756.004 44.23%
2022 -229.400.000 75.26%
2023 -128.868.000 -78.01%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Exscientia plc Gross Profit
Year Gross Profit Growth
2019 4.553.679
2020 -6.206.304 173.37%
2021 10.299.066 160.26%
2022 -7.300.000 241.08%
2023 8.560.000 185.28%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Exscientia plc Net Profit
Year Net Profit Growth
2019 -8.282.635
2020 -30.367.826 72.73%
2021 -49.272.510 38.37%
2022 -143.200.000 65.59%
2023 -124.856.000 -14.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Exscientia plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 -1 0%
2022 -1 100%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Exscientia plc Free Cashflow
Year Free Cashflow Growth
2019 6.983.270
2020 -32.435.232 121.53%
2021 -16.258.980 -99.49%
2022 -100.390.894 83.8%
2023 -38.178.000 -162.95%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Exscientia plc Operating Cashflow
Year Operating Cashflow Growth
2019 9.210.940
2020 -29.209.425 131.53%
2021 -6.668.460 -338.02%
2022 -73.235.226 90.89%
2023 -34.161.000 -114.38%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Exscientia plc Capital Expenditure
Year Capital Expenditure Growth
2019 2.227.671
2020 3.225.806 30.94%
2021 9.590.520 66.36%
2022 27.155.668 64.68%
2023 4.017.000 -576.02%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Exscientia plc Equity
Year Equity Growth
2019 28.916.453
2020 79.756.599 63.74%
2021 566.967.288 85.93%
2022 578.300.000 1.96%
2023 392.972.000 -47.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Exscientia plc Assets
Year Assets Growth
2019 54.372.738
2020 105.924.200 48.67%
2021 640.839.006 83.47%
2022 784.600.000 18.32%
2023 550.131.000 -42.62%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Exscientia plc Liabilities
Year Liabilities Growth
2019 25.456.286
2020 26.167.600 2.72%
2021 73.871.718 64.58%
2022 206.300.000 64.19%
2023 157.159.000 -31.27%

Exscientia plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.21
Net Income per Share
-1.22
Price to Earning Ratio
-4.4x
Price To Sales Ratio
22.96x
POCF Ratio
-3.78
PFCF Ratio
-2.84
Price to Book Ratio
1.7
EV to Sales
19.44
EV Over EBITDA
-3.23
EV to Operating CashFlow
-2.84
EV to FreeCashFlow
-2.4
Earnings Yield
-0.23
FreeCashFlow Yield
-0.35
Market Cap
0,59 Bil.
Enterprise Value
0,50 Bil.
Graham Number
9.31
Graham NetNet
2.11

Income Statement Metrics

Net Income per Share
-1.22
Income Quality
0.95
ROE
-0.33
Return On Assets
-0.28
Return On Capital Employed
-0.4
Net Income per EBT
0.86
EBT Per Ebit
0.93
Ebit per Revenue
-7.4
Effective Tax Rate
0.14

Margins

Sales, General, & Administrative to Revenue
1.69
Research & Developement to Revenue
5.4
Stock Based Compensation to Revenue
1.18
Gross Profit Margin
-0.28
Operating Profit Margin
-7.4
Pretax Profit Margin
-6.87
Net Profit Margin
-5.88

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.42
Free CashFlow per Share
-1.68
Capex to Operating CashFlow
0.18
Capex to Revenue
-1.24
Capex to Depreciation
-2.13
Return on Invested Capital
-0.38
Return on Tangible Assets
-0.3
Days Sales Outstanding
992.91
Days Payables Outstanding
114.19
Days of Inventory on Hand
0
Receivables Turnover
0.37
Payables Turnover
3.2
Inventory Turnover
0
Capex per Share
-0.26

Balance Sheet

Cash per Share
2,94
Book Value per Share
3,16
Tangible Book Value per Share
2.87
Shareholders Equity per Share
3.16
Interest Debt per Share
0.15
Debt to Equity
0.05
Debt to Assets
0.03
Net Debt to EBITDA
0.59
Current Ratio
6.67
Tangible Asset Value
0,36 Bil.
Net Current Asset Value
0,29 Bil.
Invested Capital
0.05
Working Capital
0,38 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,06 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Exscientia plc Dividends
Year Dividends Growth

Exscientia plc Profile

About Exscientia plc

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.

CEO
Dr. David Hallett Ph.D.
Employee
481
Address
The SchrOedinger Building
Oxford, OX4 4GE

Exscientia plc Executives & BODs

Exscientia plc Executives & BODs
# Name Age
1 Dr. David Hallett Ph.D.
Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer & Executive Director
70
2 Ms. Caroline Rowland
Chief People Officer
70
3 Mr. Parker Moss
Executive Vice President of Corporate Development
70
4 Dr. John P. Overington Ph.D.
Chief Data Officer
70
5 Mr. Dan Ireland
Vice President of Legal & Company Secretary
70
6 Dr. Michael Krams M.D.
Chief Medical Officer
70
7 Mr. Richard Law
Chief Business Officer
70
8 Ms. Sara Sherman
Vice President of Investor Relations
70
9 Mr. Ben R. Taylor
Chief Financial Officer, Chief Strategy Officer & Executive Director
70
10 Ms. Eileen Jennings-Brown
Chief Information Officer
70

Exscientia plc Competitors